GB1330878A - Ketamine resolution - Google Patents

Ketamine resolution

Info

Publication number
GB1330878A
GB1330878A GB6017370A GB6017370A GB1330878A GB 1330878 A GB1330878 A GB 1330878A GB 6017370 A GB6017370 A GB 6017370A GB 6017370 A GB6017370 A GB 6017370A GB 1330878 A GB1330878 A GB 1330878A
Authority
GB
United Kingdom
Prior art keywords
ketamine
resolution
dec
anaesthetics
anticonvulsants
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB6017370A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Co
Original Assignee
Bristol Myers Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Co filed Critical Bristol Myers Co
Publication of GB1330878A publication Critical patent/GB1330878A/en
Expired legal-status Critical Current

Links

Landscapes

  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

1330878 Ketamine resolution BRISTOL MYERS CO 18 Dec 1970 [19 Dec 1969] 60173/70 Heading C2C Ketamine is resolved with tartaric acid and the isomers may be converted to salts. These compounds are anaesthetics and anticonvulsants, and may be administered in the form of pharmaceutical preparations containing them in association with a carrier.
GB6017370A 1969-12-19 1970-12-18 Ketamine resolution Expired GB1330878A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US88679969A 1969-12-19 1969-12-19

Publications (1)

Publication Number Publication Date
GB1330878A true GB1330878A (en) 1973-09-19

Family

ID=25389797

Family Applications (1)

Application Number Title Priority Date Filing Date
GB6017370A Expired GB1330878A (en) 1969-12-19 1970-12-18 Ketamine resolution

Country Status (9)

Country Link
JP (1) JPS4948542B1 (en)
BE (1) BE760492A (en)
CH (1) CH535201A (en)
DE (1) DE2062620A1 (en)
ES (1) ES386601A1 (en)
FR (1) FR2081388B1 (en)
GB (1) GB1330878A (en)
NL (1) NL7018334A (en)
ZA (1) ZA708468B (en)

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU727528B2 (en) * 1996-05-15 2000-12-14 Cu Chemie Uetikon Gmbh Racemate separation of ketamine
EP1294659A2 (en) * 2000-06-19 2003-03-26 Cristalia Produtos Quimicos e Farmaceuticos Ltda Process for isolating enantiomers of racemic cetamine
WO2004028522A1 (en) * 2002-09-25 2004-04-08 Innovative Drug Delivery Systems, Inc. Analgesic compositions comprising nmda receptor antagonists and benzalkonium chloride
US8507525B2 (en) 2004-03-29 2013-08-13 Auris Medical Ag Methods for the treatment of tinnitus induced by cochlear excitotoxicity
US9066865B2 (en) 2005-09-28 2015-06-30 Auris Medical Ag Pharmaceutical compositions for the treatment of inner ear disorders
US9072662B2 (en) 2004-03-29 2015-07-07 Auris Medical Ag Methods for the treatment of tinnitus induced by cochlear excitotoxicity
CN107750245A (en) * 2015-05-13 2018-03-02 詹森药业有限公司 (S) -CSA salts of S-ketamine, (R) -CSA salts of S-ketamine and methods for making S-ketamine
US10709682B2 (en) 2011-12-12 2020-07-14 Otolanum Ag Treatment of tinnitus through modulation of chloride co-transporter NKCC1 in the auditory system
US10869844B2 (en) 2014-09-15 2020-12-22 Janssen Pharmaceutica Nv Methods for the treatment of depression
CN112125816A (en) * 2020-03-17 2020-12-25 国药集团工业有限公司 Racemization method of ketamine, its derivative or its salt
US11207279B2 (en) 2013-09-13 2021-12-28 National University Corporation Chiba University Application of R-ketamine and salt thereof as pharmaceuticals
US11253487B2 (en) 2018-10-05 2022-02-22 Clexio Biosciences Ltd. Method of treating major depressive disorder
US11426367B2 (en) 2018-05-04 2022-08-30 Perception Neuroscience, Inc. Methods of treating substance abuse
US11446260B2 (en) 2013-03-15 2022-09-20 Janssen Pharmaceutica Nv Pharmaceutical composition of S-ketamine hydrochloride
US11707440B2 (en) 2017-12-22 2023-07-25 Janssen Pharmaceuticals, Inc. Esketamine for the treatment of depression
US11883526B2 (en) 2019-03-05 2024-01-30 Janssen Pharmaceutica Nv Esketamine for the treatment of depression
US11980596B2 (en) 2017-09-13 2024-05-14 Janssen Pharmaceutica Nv Delivery of esketamine for the treatment of depression
US11980595B2 (en) 2018-02-15 2024-05-14 National University Corporation Chiba University Preventive or therapeutic agent and pharmaceutical composition for inflammatory diseases or bone diseases
US12036189B2 (en) 2018-06-27 2024-07-16 Clexio Biosciences Ltd. Method of treating major depressive disorder
US12076300B2 (en) 2019-12-30 2024-09-03 Clexio Biosciences Ltd. Dosage regime with esketamine for treating major depressive disorder

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5875614A (en) * 1981-10-28 1983-05-07 Matsushita Electric Ind Co Ltd Exhaust gas purifying device for incinerator
DE4312016A1 (en) * 1993-04-13 1994-10-20 Goedecke Ag Stable ketamine solutions
US8268866B2 (en) 2004-03-29 2012-09-18 Matthieu Guitton Methods for the treatment of tinnitus induced by cochlear excitotoxicity
JP6545788B2 (en) 2014-08-13 2019-07-17 ヤンセン ファーマシューティカ エヌ．ベー． How to treat depression
CN110218157B (en) * 2018-03-01 2022-08-23 江苏恒瑞医药股份有限公司 Preparation method of R-ketamine and its medicinal salt
WO2020070547A1 (en) 2018-10-05 2020-04-09 Clexio Biosciences Ltd. Dosage regime of esketamine for treating major depressive disorder
WO2020070706A1 (en) 2018-10-05 2020-04-09 Clexio Biosciences Ltd. Dosage regime of esketamine for treating major depressive disorder
WO2020075134A1 (en) 2018-10-11 2020-04-16 Clexio Biosciences Ltd. Esketamine for use in treating major depressive disorder
WO2021137148A1 (en) 2019-12-30 2021-07-08 Clexio Biosciences Ltd. Dosage regime with esketamine for treating neuropsychiatric or neurological conditions

Cited By (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU727528B2 (en) * 1996-05-15 2000-12-14 Cu Chemie Uetikon Gmbh Racemate separation of ketamine
EP1294659A2 (en) * 2000-06-19 2003-03-26 Cristalia Produtos Quimicos e Farmaceuticos Ltda Process for isolating enantiomers of racemic cetamine
EP1294659A4 (en) * 2000-06-19 2005-06-22 Cristalia Produtos Quimicos E Process for isolating enantiomers of racemic cetamine
WO2004028522A1 (en) * 2002-09-25 2004-04-08 Innovative Drug Delivery Systems, Inc. Analgesic compositions comprising nmda receptor antagonists and benzalkonium chloride
US7273889B2 (en) 2002-09-25 2007-09-25 Innovative Drug Delivery Systems, Inc. NMDA receptor antagonist formulation with reduced neurotoxicity
US8507525B2 (en) 2004-03-29 2013-08-13 Auris Medical Ag Methods for the treatment of tinnitus induced by cochlear excitotoxicity
US10966940B2 (en) 2004-03-29 2021-04-06 Institut National De La Sante Et De La Recherche Medicale (Inserm) Methods for the treatment of tinnitus induced by cochlear excitotoxicity
US9072662B2 (en) 2004-03-29 2015-07-07 Auris Medical Ag Methods for the treatment of tinnitus induced by cochlear excitotoxicity
US9463168B2 (en) 2004-03-29 2016-10-11 Institut National De La Sante Et De La Recherche Medicale (Inserm) Methods for the treatment of tinnitus induced by cochlear excitotoxicity
US9066865B2 (en) 2005-09-28 2015-06-30 Auris Medical Ag Pharmaceutical compositions for the treatment of inner ear disorders
US10709682B2 (en) 2011-12-12 2020-07-14 Otolanum Ag Treatment of tinnitus through modulation of chloride co-transporter NKCC1 in the auditory system
US11446260B2 (en) 2013-03-15 2022-09-20 Janssen Pharmaceutica Nv Pharmaceutical composition of S-ketamine hydrochloride
US11207279B2 (en) 2013-09-13 2021-12-28 National University Corporation Chiba University Application of R-ketamine and salt thereof as pharmaceuticals
US11173134B2 (en) 2014-09-15 2021-11-16 Janssen Pharmaceutica Nv Methods for the treatment of depression
US10869844B2 (en) 2014-09-15 2020-12-22 Janssen Pharmaceutica Nv Methods for the treatment of depression
US11311500B2 (en) 2014-09-15 2022-04-26 Janssen Pharmaceutica Nv Methods for the treatment of depression
CN107750245A (en) * 2015-05-13 2018-03-02 詹森药业有限公司 (S) -CSA salts of S-ketamine, (R) -CSA salts of S-ketamine and methods for making S-ketamine
US11980596B2 (en) 2017-09-13 2024-05-14 Janssen Pharmaceutica Nv Delivery of esketamine for the treatment of depression
US11707440B2 (en) 2017-12-22 2023-07-25 Janssen Pharmaceuticals, Inc. Esketamine for the treatment of depression
US11980595B2 (en) 2018-02-15 2024-05-14 National University Corporation Chiba University Preventive or therapeutic agent and pharmaceutical composition for inflammatory diseases or bone diseases
US11426367B2 (en) 2018-05-04 2022-08-30 Perception Neuroscience, Inc. Methods of treating substance abuse
US12036189B2 (en) 2018-06-27 2024-07-16 Clexio Biosciences Ltd. Method of treating major depressive disorder
US11865088B2 (en) 2018-10-05 2024-01-09 Clexio Biosciences Ltd. Method of treating major depressive disorder
US11957645B2 (en) 2018-10-05 2024-04-16 Clexio Biosciences Ltd. Method of treating major depressive disorder
US11253487B2 (en) 2018-10-05 2022-02-22 Clexio Biosciences Ltd. Method of treating major depressive disorder
US12016832B2 (en) 2018-10-05 2024-06-25 Clexio Biosciences Ltd. Method of treating major depressive disorder
US11883526B2 (en) 2019-03-05 2024-01-30 Janssen Pharmaceutica Nv Esketamine for the treatment of depression
US12076300B2 (en) 2019-12-30 2024-09-03 Clexio Biosciences Ltd. Dosage regime with esketamine for treating major depressive disorder
CN112125816A (en) * 2020-03-17 2020-12-25 国药集团工业有限公司 Racemization method of ketamine, its derivative or its salt

Also Published As

Publication number Publication date
FR2081388B1 (en) 1974-06-21
FR2081388A1 (en) 1971-12-03
JPS4948542B1 (en) 1974-12-21
ES386601A1 (en) 1974-01-16
CH535201A (en) 1973-03-31
ZA708468B (en) 1972-02-23
DE2062620A1 (en) 1971-07-15
NL7018334A (en) 1971-06-22
BE760492A (en) 1971-06-17

Similar Documents

Publication Publication Date Title
GB1330878A (en) Ketamine resolution
AU467578B2 (en) New cyclic urea derivatives and salts thereof process forthe production thereof and pharmaceutical preparations containing thesame
GB1281719A (en) Anti-haemorrhoidally active preparations for local or rectal administration
CA984849A (en) Metal complexes of n,n'-dialkylesters of ethylenedinitrilotetraacetic acid and compositions stabilized thereby
GB1051686A (en)
CA970107A (en) Dyeing of polycarbonamides of bis(paraaminocyclohexyl) methane and dodecanedioic acid with anionic dyes
IL38467A0 (en) 6-aminopenicillanic acid derivatives,their manufacture and pharmaceutical compositions containing them
IL36487A0 (en) Derivatives of phenyl-azolyl-fatty acids,their production and their use as medicines
GB1191554A (en) New Analgesic Composition.
ES430306A1 (en) D-homosteroids
CA839229A (en) Local anesthetic composition for topical application and process of making and using same
AU419560B2 (en) Improvements inthe administration of insulin
IL39743A0 (en) Quinazoline derivatives,their production and pharmaceutical compositions containing them
CA970088A (en) Stable solutions of polyglutamic acid derivatives
AU405610B2 (en) Improvements in and relating to novel, 9, 10 - steroids, methods of producing the same, pharmaceutic preparations containing said 9, 10 - steroids as active substances and methods of producing said preparations
GB1266454A (en)
AU6164065A (en) Improvements in and relating to novel, 9, 10 - steroids, methods of producing the same, pharmaceutic preparations containing said 9, 10 - steroids as active substances and methods of producing said preparations
GB1357845A (en) Esters
GB1469208A (en) Diphenylpyraline salt
CA868933A (en) Production of nitrilo-triacetic acid and analogs thereof
GB1268783A (en) Benzodiazepine derivatives
GB1171599A (en) Dermatological Composition
AU282206B2 (en) Improvements in and relating to novel spirol-acetones of the steroid series, novel methods of producing said compounds and pharmaceutical preparations containing said compounds as active substances
AU265043B2 (en) New derivatives of pyrazine, process of preparing thesame and pharmaceutical preparations containing them
AU410357B2 (en) Injectable insulin preparations for clinical use and process for their production

Legal Events

Date Code Title Description
PS Patent sealed
PCNP Patent ceased through non-payment of renewal fee